GAO Study Doesn’t Cite Drug Discounts as a Major Factor in Shortages

by Admin | February 11, 2014 1:40 pm

February 11, 2014—Halts or slowdowns in manufacturing to address quality problems are the leading immediate cause of drug shortages, especially among generic sterile injectable products, the Government Accountability Office (GAO) concluded in a long awaited report[1] yesterday. It recommended that the Food and Drug Administration (FDA) strengthen its internal controls over its drug shortage data and conduct periodic analyses to assess drug shortage information routinely and systematically.

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[2]. Already registered? Click here to login[3]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Endnotes:

a long awaited report: http://www.gao.gov/products/GAO-14-339T
Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2014/02/gao-study-doesnt-cite-drug-discounts-as-a-major-factor-in-shortages/